1.	Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: 20050113, NCT00243685
2.	Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: EORTC-62012, NCT00061984
3.	Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Phase: Phase III Type: Treatment Status: Active Age: Under 50 Sponsor: NCI Protocol IDs: COG-ARST0331, NCT00075582, ARST0331
4.	Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Phase: Phase III Type: Treatment Status: Active Age: Under 30 at diagnosis Sponsor: NCI Protocol IDs: COG-ARST0332, ARST0332, NCT00346164
5.	Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Phase: Phase III Type: Treatment Status: Active Age: Under 50 Sponsor: NCI Protocol IDs: COG-ARST0531, NCT00354835, ARST0531
6.	Radiation Therapy in Treating Patients Who Have Undergone Surgery for Soft Tissue Sarcoma of the Arms, Hands, Legs, or Feet Phase: Phase III Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: CRUK-VORTEX, EU-20678, ISRCTN76456502, CRCTU-SA3002, NCT00423618
7.	Observation Versus Post-Surgery Radiotherapy After Complete Exeresis in Soft Tissues Members Sarcoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08SARC01, NCT00870701
8.	Trial for Localised High-Risk Rhabdomyosarcoma and Rhabdomyosarcoma-Like Soft Tissue Sarcoma Phase: Phase III Type: Treatment Status: Active Age: 6 months to 21 years Sponsor: Other Protocol IDs: CWS-2007-HR, 4033024 (BfArM), 293/2007AMG1 (Ethikkommission), 2007-001478-10 (EUDRACT), A2007/14 (Kinderkrebsstiftung), 498 (Krebsstudienregister), NCT00876031
9.	Hyperthermia, Radiation Therapy, Surgery, and Optional Chemotherapy in Treating Patients With Soft Tissue Sarcoma of the Limbs Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: DUMC-1308-04-7R5, DUMC-G040102, DUMC-G880018, NCT00093509
10.	Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CHNMC-04090, NCT00233948
11.	Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: ASSG01, NCT00753727
12.	Radiation Therapy, Sorafenib, and Surgery in Treating Patients With Soft Tissue Sarcoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCDCC-216, UCDCC#216, BAYER-UCDCC-216, NCT00805727
13.	Study of PXD101 and Doxorubicin to Treat Soft Tissue Sarcomas Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PXD101-CLN-14, NCT00878800
14.	Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma Phase: Phase II Type: Treatment Status: Active Age: 30 and under at diagnosis Sponsor: NCI Protocol IDs: MSKCC-03099, NCT00077285
15.	Radiation Therapy to Treat Musculoskeletal Tumors Phase: Phase II Type: Treatment Status: Active Age: 25 and under Sponsor: Other Protocol IDs: RTSARC, NCT00186992
16.	IMRT Lower Limb Soft Tissue Sarcoma Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: 03-0107-C, NCT00188175
17.	Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma Phase: Phase II Type: Treatment Status: Active Age: 10 and over Sponsor: Other Protocol IDs: UMCC 2004.010, NCT00189137
18.	Bevacizumab in Treating Patients With Angiosarcoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NU-04S1, NCT00288015
19.	Bevacizumab and Radiation Therapy for Sarcomas Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 05-090, 1 R21 CA117128-01A1, NCT00356031
20.	Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: NCI Protocol IDs: CINJ-3330, NCT00161187
21.	Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0630, RTOG 0630, NCT00589121
22.	Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas Phase: Phase II Type: Treatment Status: Active Age: 30 and under Sponsor: NCI, Other Protocol IDs: 05-326, NCT00592293
23.	Proton RT for the Treatment of Pediatric Rhabdomyosarcoma Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: NCI, Other Protocol IDs: 04-188, NCT00592592
24.	Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CHNMC-07216, 07216, NCT00740597
25.	A Scandinavian Sarcoma Group Protocol for Patients With High-Risk Soft Tissue Sarcoma of the Extremities and Trunk Wall Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: EudraCT number 2007-001152-39, NCT00790244